Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Limitations of current therapies
18 evidence topics · 22 sources
Summary: response, survival, and PD-L1 selection with first-line pembrolizumab regimens
Pembrolizumab monotherapy is approved for first-line recurrent or metastatic HNSCC with PD-L1 CPS ≥1, and pembrolizumab with platinum and fluorouracil for all first-line patients. ASCO states that “Response rates to single-agent pembrolizumab remain close to 20%, regardless of prior exposure to therapy or PD-L1 expression”. At the KEYNOTE-048 4-year follow-up, the objective response rate with pembrolizumab alone was 19.1% versus 34.9% with cetuximab-chemotherapy in the CPS ≥1 population and 16.9% versus 36.0% in the total population; with pembrolizumab-chemotherapy it was 37.2% (CPS ≥1) and 36.3% (total). Neither pembrolizumab regimen improved progression-free survival at the second interim analysis, when median progression-free survival in the CPS ≥1 subgroup was 3.2 months with pembrolizumab versus 5.0 months with cetuximab-chemotherapy. At the 4-year follow-up, median overall survival was 12.3 months with pembrolizumab (CPS ≥1) and 13.0 months with pembrolizumab-chemotherapy (total population); 5-year overall survival in the total population was 14.4% and 16.0%, and the survival curve with pembrolizumab alone reached a plateau at approximately 20%. The median duration of pembrolizumab exposure was 3.5 months with monotherapy and 5.8 months in the combination arm. In exploratory analyses that were not prespecified, median overall survival with pembrolizumab alone versus cetuximab-chemotherapy was 10.8 versus 10.1 months in the CPS 1-19 subgroup (hazard ratio 0.86, 95% CI 0.66 to 1.12), and median overall survival was 7.9 versus 11.3 months in the CPS <1 subgroup (hazard ratio 1.51, 95% CI 0.96 to 2.37).
Summary: toxicity and administration of chemotherapy-containing regimens
At the KEYNOTE-048 4-year follow-up, grade ≥3 treatment-related adverse events occurred in 17.0% of participants receiving pembrolizumab alone, 71.7% receiving pembrolizumab-chemotherapy, and 69.3% receiving cetuximab-chemotherapy. Fluorouracil requires a “continuous 4-day infusion” and is associated with “cardiovascular and gastrointestinal toxicities”. In EXTREME, fatal cardiac disorders or sudden death occurred in 3% of 219 participants treated with cetuximab plus platinum and fluorouracil. With a taxane in place of fluorouracil alongside pembrolizumab and carboplatin, grade 3 to 5 treatment-related adverse events occurred in 76 of 101 treated participants (75%). NCI states that chemotherapy has been shown to induce responses with no demonstrated increase in survival; in randomized trials, cisplatin plus fluorouracil did not improve overall survival over methotrexate, and response rates were 32% with cisplatin plus fluorouracil and 10% with methotrexate in one trial, and 27% with cisplatin plus fluorouracil and 26% with cisplatin plus paclitaxel in another.
Summary: outcomes in HPV-negative disease
Response and survival with current therapy are lower in HPV-negative than in HPV-positive disease. In Argiris et al. (2014), the objective response rate was 19% for HPV-negative versus 55% for HPV-positive tumors, and median survival was 6.7 versus 12.9 months. After progression of oropharyngeal cancer, 2-year overall survival was 27.6% for p16-negative versus 54.6% for p16-positive disease. With first-line pembrolizumab in U.S. practice, median real-world overall survival in HPV-negative versus HPV-positive disease was 9 versus 20 months on monotherapy and 7 versus 15 months with chemotherapy. ASCO states that current data “do not support changing recommendations” for anti-PD-1 therapy “with regard to the HPV status.”
Summary: options after progression and for locoregional recurrence
The FDA states that approved therapies after platinum-based chemotherapy are associated with an overall response rate of around 20% or less. On November 5, 2026, amivantamab and hyaluronidase-lpuj received accelerated approval after progression on platinum-based chemotherapy and an anti-PD-(L)1 antibody, excluding HPV-associated oropharyngeal squamous cell carcinoma, based on an overall response rate of 42% in the 102-participant primary efficacy population of OrigAMI-4, a multicenter, open-label, multi-cohort trial. Conventional salvage regimens yield response rates of 21% to 69%, median progression-free survival of 2.9 to 5.5 months, and median overall survival of 6.3 to 13.3 months, and a review states that there is “no clear standard of care choice in second-line treatment”. For locoregional recurrence after prior radiation, reirradiation with intensity-modulated radiotherapy had pooled late grade ≥3 and grade 5 toxicity rates of 26% and 3.1%, and postoperative reirradiation with chemotherapy after salvage surgery improved disease-free survival without a significant effect on overall survival.
Response rates with pembrolizumab monotherapy
Objective response in KEYNOTE-048 at 4-year follow-up
“Pembrolizumab alone did not improve ORR compared with cetuximab-chemotherapy in the PD-L1 CPS ≥ 20, CPS ≥ 1, or total populations” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ORR was 23.3% (11 CR/20 PR) for pembrolizumab alone versus 36.1% (4 CR/40 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 19.1% (15 CR/34 PR) versus 34.9% (7 CR/82 PR) in the CPS ≥ 1 population, and 16.9% (15 CR/36 PR) versus 36.0% (8 CR/100 PR) in the total population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The ORR was 43.7% (13 CR/42 PR) for pembrolizumab-chemotherapy versus 38.2% (4 CR/38 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 37.2% (17 CR/73 PR) versus 35.7% (7 CR/77 PR) in the CPS ≥ 1 population, and 36.3% (18 CR/84 PR) versus 36.3% (8 CR/93 PR) in the total population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term survival plateau in KEYNOTE-048
“A survival plateau at approximately 20% became apparent around the 4-year landmark for all patients receiving pembrolizumab alone. For patients receiving pembrolizumab-chemotherapy, a survival plateau at approximately 30% was observed for the PD-L1 CPS ≥ 20 population and at approximately 20% for the CPS ≥ 1 and total populations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment-related adverse events with pembrolizumab plus chemotherapy
“Any-grade treatment-related AEs occurred in 58.3% (n = 175) of patients in the pembrolizumab-alone group, 95.7% (n = 264) in the pembrolizumab-chemotherapy group, and 96.9% (n = 278) in the cetuximab-chemotherapy group” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Grade ≥ 3 treatment-related AEs were reported in 17.0% (n = 51), 71.7% (n = 198), and 69.3% (n = 199) of patients, respectively” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Fluorouracil administration and toxicity
“However, FU is associated with potential challenges (continuous 4-day infusion, high administration costs, and cardiovascular and gastrointestinal toxicities), creating a clinical need for alternative chemotherapy combinations.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cardiac deaths with cetuximab plus platinum and fluorouracil
HPV-negative disease: response and survival with first-line chemotherapy
“The objective response rate was 55% for HPV-positive versus 19% for HPV-negative (P = 0.022), and 50% for p16-positive versus 19% for p16-negative (P = 0.057).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median survival was 12.9 versus 6.7 months for HPV-positive versus HPV-negative patients (P = 0.014), and 11.9 versus 6.7 months for p16-positive versus p16-negative patients (P = 0.027).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
HPV-negative disease: survival after progression of oropharyngeal cancer
HPV-negative disease: real-world survival with first-line pembrolizumab
“Among those receiving pembrolizumab monotherapy, the median rwOS was 20 months for those with HPV-positive tumors versus 9 months for those with HPV-negative tumors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among individuals receiving pembrolizumab plus chemotherapy, the median rwOS was 15 months for those with HPV-positive tumors versus 7 months for those with HPV-negative tumors” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Prognosis and later-line options before immunotherapy
“The prognosis of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) remains poor, with a guarded median overall survival (OS) ranging from 10 months to 14 months” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Upon progression, the only treatment option was single-agent chemotherapy, with limited response rates and a median survival of 6 months” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Unmet need stated by the FDA
Unmet need after immune checkpoint inhibitor failure
“The challenge of R/M HNSCC after immune checkpoint inhibitor (ICI) failure represents one of the most pressing unmet needs in oncology.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Between 60 and 80% of patients develop resistance, and historical salvage regimens like cytotoxic chemotherapy or chemotherapy plus cetuximab rarely extend median overall survival (mOS) beyond one year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote